This inventor holds 2 USPTO granted patents. Top assignee: The United States of America as Represented by the Department of Health. Active years: 1996-1998.
Company Filing History:
Years Active: 1996-1998
Title: The Innovations of Matti Virkkunen
Introduction
Matti Virkkunen is a notable inventor based in Helsinki, Finland. He has made significant contributions to the field of genetics and neuroscience, particularly in understanding the serotonergic system. With a total of 2 patents, his work has implications for both medical research and treatment.
Latest Patents
Matti Virkkunen's latest patents include groundbreaking discoveries. The first patent, titled "Allelic variation of the serotonin 5HT7 receptor," involves the identification of an allelic variant of the 5HT7 serotonin receptor. Family study data suggest that this variant may correlate with alcoholic offenders. The invention encompasses DNA encoding the variant protein, the protein itself, vectors containing the variant gene, and cell lines carrying a vector with the variant gene. The second patent, "Method for detecting abnormal serotonergic function," presents a method for detecting abnormal serotonergic function in impulsive human subjects. This method includes detecting an L allele of a gene encoding tryptophan hydroxylase. Additionally, the invention features an isolated nucleic acid with a sequence specific to the L allele of the gene, which migrates in a denaturing gel at the same rate as a second nucleic acid specific to a corresponding region of a U allele.
Career Highlights
Matti Virkkunen has had a distinguished career, working with the United States of America as represented by the Department of Health. His research has contributed to a deeper understanding of genetic factors influencing behavior and mental health.
Collaborations
Throughout his career, Matti has collaborated with esteemed colleagues, including Markku I Linnoila and David Goldman. These partnerships have enhanced the impact of his research and broadened the scope of his inventions.
Conclusion
Matti Virkkunen's innovative work in genetics and neuroscience has led to significant advancements in understanding the serotonergic system. His patents reflect a commitment to improving mental health treatment and research.